Genetic code is inherited and it’s unique. Within our genes, different variations affect how we react to certain drugs and treatments for diseases, including cancer. The RGCC ChemoSNiP test provides information about Single Nucleotide Polymorphism that can affect how humans develop cancer or respond to anti-cancer drugs and treatments.
ChemoSNiP
Whole peripheral blood sample
10-15ml blood
All Types
30 days
RGCC ChemoSNiP is an advanced and innovative test that uses pharmacokinetics technology to assess your body’s response to specific anti-cancer drugs. The test reveals how your body metabolizes and reacts to cancer drugs, enabling clinicians to tailor therapies for optimal outcomes. It equips you with personalized information to ensure the most effective and targeted treatment plan tailored to your individual needs.
DNA is extracted from a blood sample and is used as a template in PCR reactions. Molecular-based assays and spectrophotometer analysis are used to verify SNP (Single Nucleotide Polymorphism) or variations.
RGCC ChemoSNIP test studies single nucleotide polymorphisms in a patient’s genes that are involved in breaking down cytostatic (anti-cancer) or targeted drugs that are used to treat cancer therapy.
Single Nucleotide Polymorphisms (SNPs) denote variations within the DNA sequence. These SNPs are pivotal as they determine how inherited genetic differences impact an individual's response to drugs.
The test employs pharmacokinetics to meticulously examine how the body metabolizes anti-cancer drugs, providing crucial insights into drug efficacy.
Pharmacokinetics examines how drugs are absorbed, distributed, metabolized, and excreted within the body over time.
It plays a critical role in understanding how anti-cancer drugs interact with the body and provides invaluable insights into the pharmacological behavior of anti-cancer drugs, guiding personalized treatment strategies tailored to individual patient needs and optimizing therapeutic outcomes in cancer therapy.
RGCC ChemoSNiP test provides a personalized analysis of a patient's DNA providing information on the most effective combination of drugs and treatments available to that patient
Having this type of personalized information available even before your treatment begins can be crucial to the success of your cancer treatment journey.
The test provides clinicians with crucial information about the ability of every individual to break down and trigger a treatment most effectively.
The ChemoSNiP test evaluates how your body responds to the specific anti-cancer drug by analyzing SNPs. The test answers which chemotherapeutic drug works best for your cancer and which doesn’t.
The test applies to all types of cancers and not just limited to the following.
The first step towards personalized cancer care is scheduling an appointment with us.
Upon booking the appointment, you get a consultation with our RGCC experts to assess your cancer status.
We guide you through the process of selecting the most effective tests for your specific cancer.
We deliver precise results that guide treatment decisions and enhance outcomes.
Our RGCC accredited experts are here to help you with their expertise and guide you in your fight against cancer.
We recommend ChemoSNiP before starting chemotherapy as it will help the clinician to under whether the patient is a rapid metaboliser, normal metaboliser, or poor metaboliser.
When used together with data from chemosensitivity testing, ChemoSNiP helps to narrow the selection to the most effective and least toxic therapeutic agent.
Our cutting edge diagnostics and personalised tests makes a meaningful difference in the fight against cancer.
Absolutely, tests can be performed while undergoing treatment to assess the effectiveness of the treatment against cancer.
RGCC Metastat is an effective test for identifying secondary tumors development and its potential location. It helps detect secondary tumors through analyzing Circulating Tumor Cells (CTCs) in the bloodstream. The test provides valuable insights into disease progression and metastasis.
Your blood sample undergoes processing in cutting-edge laboratories by scientists and technicians to deliver insights into your cancer cells.
Tests personalize treatment regimens by providing crucial information on drugs and therapies tailored to effectively target cancer cells.
Yes, all RGCC tests utilize blood samples. However, certain cancers, like glioblastoma and brain tumors, may require additional samples such as CSF or tissue. Otherwise, a peripheral blood sample alone is enough.
Circulating Tumor Cells (CTCs) are cancer cells that have detached from the primary tumor and circulate in the bloodstream. Cancer Stem Cells (CSCs) are a subpopulation of CTCs and both serve as biomarkers for cancer.
Yes, tests like aCGH can pinpoint the origin of an unknown primary tumor by analyzing genetic abnormalities present in tumor cells.
Tests like ChemoSNiP and CAMBISeq provide information on the body’s response to the drugs and sensitivity to immunotherapy.
Looking for the most effective drug for your targeted cancer care? RGCC ChemoSNiP test analyzes your blood sample to identify which drugs will be most effective in treating your cancer. By analyzing DNA variations, RGCC ChemoSNiP delivers impactful results, offering long-term relief by eliminating cancer.
Offering personalized tests from RGCC, our mission is to improve treatment outcomes, enhance survival rates, and elevate overall quality of life for those affected by cancer.
Copyright 2024 © All Right Reserved.
Designed by Bee High Media
Dr. Noorul Ameen